Amalia Ruiz

Amalia Ruiz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amalia Ruiz has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Innovative Nanocarriers of Sorafenib in the Optimisation of Therapeutic Outcome: Challenges and Applications in Breast Cancer

    by Nishtha Chaurawal, Amalia Ruiz Estrada, Klaus Pors, Kaisar Raza, Muhammad Wahajuddin

    Sorafenib is an oral tyrosine kinase inhibitor which inhibits the growth of cancer cells by inhibiting several tyrosine kinase receptors taking part in the perpetuation and pathogenesis of breast tumours. Sorafenib was approved in 2005 for the treatment of liver and prostate cancers. In recent years, focused studies have explored the drugs clinical potential in breast cancer. There are several clinical trials (ongoing and completed) of sorafenib to treat metastatic breast cancer patients. Interestingly, these have shown encouraging results in particular in combination with other clinically-used drugs. However, effective clinical use has been somewhat hampered due to the drug's hydrophobicity, rapid first pass metabolism, short half-life, low oral bioavailability and side effects including hand and foot reaction as well as hypersensitivity. In attempts to overcome some of these drawbacks, nanotechnology-based delivery systems have been explored including nanocarriers like liposomes, niosomes, lipid-polymer hybrid nanoparticles, solid lipid nanocarriers, microemulsions, nanovectors and gel matrices. We will describe current state-of-the-art nanocarrier-based strategies, and discuss how such approaches can be harnessed to enhance the clinical efficacy of sorafenib for breast cancer treatment.

  • Open Access

    Thera-regenerative hydrogel co-loaded with black phosphorus quantum dots and CD44-targeted nanoparticles for metastatic prostate cancer treatment

    by Louis-Marie Roudillon, Harriet R. Walker, Luz Izquierdo Juliá, Bana Shriky, María Elena Varona Pérez, Stuart Fox, Jacobo Elies, Ethan Perkins, Muhammad Wahajuddin, Cristina Martín, et al.

  • Open Access

    Machine Learning-Driven Drug Repurposing Investigation to Identify New Tubulin Inhibitors Against Cancer

    by Neelima Neelima, Hussein Elrewey, Sneha Swaroop, Amalia Ruiz Estrada, Muhammad Wahajuddin, Gaurav Joshi, Vibhu Jha

    Tubulin is one of the major structural proteins that exists either as free forms or as microtubules. These microtubules have unique characteristics, termed as ‘exquisite dynamic behavior’, that is associated with the polymerization and depolymerization of the microtubules or the tubulin units. In cancer cells, the tubulin-mediated dynamicity is lost owing to the elevated expression and functioning of microtubules. These lead to uncontrolled cancer cell proliferation, evading controlled cell cycle checks, survival, and resistance to existing cancer chemotherapy. Considering this, the tubulins/microtubules are validated drug targets in cancer. The agents targeting the microtubules are called microtubule-targeting agents (MTAs). These agents are further subclassified into three groups and act at 7 druggable sites identified so far. However, the majority of inhibitors approved are phytochemicals and are semisynthetic-derived, which are associated with poor pharmacokinetics and toxicities that hamper their clinical use. The rapidly growing cancer cases globally demands rapid drug discovery. One of the rapid and recommended ways for drug discovery is drug repurposing or repositioning. To achieve this, we employed machine learning (ML)-driven, integrated with in silico-based high-throughput virtual screening of 4500 FDA-approved compounds to identify new tubulin inhibitors interacting with the Colchicine Binding Site (CBS) with anticancer potential. The virtual screening workflow was supported by structure-based drug design approaches including three stages of molecular docking, MM-GBSA binding free energy calculations and molecular dynamics (MD) simulations, leading to a refined library of potential tubulin inhibitors. The best hit compounds were tested biochemically to verify tubulin inhibition, as well as tested against a panel of cancer cell lines, whereby Omeprazole and Podofilox demonstrated promising results. The outcomes of this work may lay a solid foundation for further drug development projects, targeting tubulin and cancer via drug repurposing.

  • Open Access

    Magnetically induced drug release from niosome-based nanocarriers loaded with doxorubicin

    by Philip Drake, Ilma Amalina, Retno Sari, Amalia Ruiz, Saliha Ramazan, Gordon Hope, Dharmisthaben Pancholi, Andang Miatmoko

    Niosomes co-loaded with doxorubicin and magnetic nanoparticles were synthesised using the thin film hydration method. The loading efficiency of the doxorubicin was between 60-70%. The hydrodynamic diameter measured as the average number (mean ± standard deviation), using dynamic light scattering, was found to be 188 ± 68 nm, 141 ± 86 nm and 169 ± 69 nm for the plain niosomes, niosomes loaded with doxorubicin and niosomes loaded with doxorubicin and magnetic nanoparticles, respectively. The zeta potential for all three niosome samples was determined to be -26.4 mV ± 1.9 mV. The thermally mediated release of doxorubicin was monitored using fluorescence spectroscopy and found to follow 1st order kinetics. The rate constant for the thermal release was 1.2x10-6, 1.0x10-4 and 5.1x10-4 min-1 at 298, 313 and 333 K, respectively. The doxorubicin was also released using an alternating magnetic field, this also followed 1st order kinetics and had a rate constant of 1.7x10-2 min-1. This is four orders of magnitude greater than the thermal release at the same temperature (298 K). The work shows the magnetically controlled, burst release from a drug-loaded niosome delivery system. The release was triggered on demand by the application of the alternating magnetic field, resulting in 86% doxorubicin release within 3 hours compared to 3% release in 30 days via thermal release.


  • Open Access

    Piezoelectric Nanomaterials for Cancer Therapy: Current Research and Future Perspectives on Glioblastoma

    by Zayne Knight, Amalia Ruiz, Jacobo Elies

    Cancer significantly impacts human quality of life and life expectancy, with an estimated 20 million new cases and 10 million cancer-related deaths worldwide every year. Standard treatments including chemotherapy, radiotherapy, and surgical removal, for aggressive cancers, such as glioblastoma, are often ineffective in late stages. Glioblastoma, for example, is known for its poor prognosis post-diagnosis, with a median survival time of approximately 15 months. Novel therapies using local electric fields have shown anti-tumour effects in glioblastoma by disrupting mitotic spindle assembly and inhibiting cell growth. However, constant application poses risks like patient burns. Wireless stimulation via piezoelectric nanomaterials offers a safer alternative, requiring ultrasound activation to induce therapeutic effects, such as altering voltage-gated ion channel conductance by depolarising membrane potentials. This review highlights the piezoelectric mechanism, drug delivery, ion channel activation, and current technologies in cancer therapy, emphasising the need for further research to address limitations like biocompatibility in whole systems. The goal is to underscore these areas to inspire new avenues of research and overcome barriers to developing piezoelectric nanoparticle-based cancer therapies.


  • Open Access

    CD-44 targeted nanoparticles for combination therapy in an in vitro model of triple-negative breast cancer: Targeting the tumour inside out

    by Silvia Gómez-Pastor, Auréane Maugard, Harriet R. Walker, Jacobo Elies, Kaja E. Børsum, Giulia Grimaldi, Giacomo Reina, Amalia Ruiz


  • Open Access

    Engineering PSMA-targeted nanoparticles co-encapsulating mitoxantrone and indocyanine green for precise combinatory therapy in prostate cancer

    by Hafiza Javeria Khalid, Sobia Khan, Danyaal Hussain, Amarachi Obinyima, Clara Pina, Harriet Rose Walker, Yolanda Pérez, Stuart Fox, Jacobo Elies, María José Gómara, et al.


  • Open Access

    Light-Responsive and Antibacterial Graphenic Materials as a Holistic Approach to Tissue Engineering

    by Andrea Ferreras, Ana Matesanz, Jabier Mendizabal, Koldo Artola, Yuta Nishina, Pablo Acedo, José L. Jorcano, Amalia Ruiz, Giacomo Reina, Cristina Martín

    While the continuous development of advanced bioprinting technologies is under fervent study, enhancing the regenerative potential of hydrogel-based constructs using external stimuli for wound dressing has yet to be tackled. Fibroblasts play a significant role in wound healing and tissue implants at different stages, including extracellular matrix production, collagen synthesis, and wound and tissue remodeling. This study explores the synergistic interplay between photothermal activity and nanomaterial-mediated cell proliferation. The use of different graphene-based materials (GBM) in the development of photoactive bioinks is investigated. In particular, we report the creation of a skin-inspired dressing for wound healing and regenerative medicine. Three distinct GBM, namely, graphene oxide (GO), reduced graphene oxide (rGO), and graphene platelets (GP), were rigorously characterized, and their photothermal capabilities were elucidated. Our investigations revealed that rGO exhibited the highest photothermal efficiency and antibacterial properties when irradiated, even at a concentration as low as 0.05 mg/mL, without compromising human fibroblast viability. Alginate-based bioinks alongside human fibroblasts were employed for the bioprinting with rGO. The scaffold did not affect the survival of fibroblasts for 3 days after bioprinting, as cell viability was not affected. Remarkably, the inclusion of rGO did not compromise the printability of the hydrogel, ensuring the successful fabrication of complex constructs. Furthermore, the presence of rGO in the final scaffold continued to provide the benefits of photothermal antimicrobial therapy without detrimentally affecting fibroblast growth. This outcome underscores the potential of rGO-enhanced hydrogels in tissue engineering and regenerative medicine applications. Our findings hold promise for developing game-changer strategies in 4D bioprinting to create smart and functional tissue constructs with high fibroblast proliferation and promising therapeutic capabilities in drug delivery and bactericidal skin-inspired dressings.


  • Open Access

    Oligo(styryl)benzenes liposomal AIE-dots for bioimaging and phototherapy in an in vitro model of prostate cancer

    by Víctor Vázquez-Villar, Chandrima Das, Thomas Swift, Jacobo Elies, Juan Tolosa, Joaquín C. García-Martínez, Amalia Ruiz


  • Open Access

    Insight into the liposomal encapsulation of mono and bis-naphthalimides

    by Abdullahi Magaji Dauda, Thomas Swift, Richard Telford, Hend A. A. Abd El-Wahab, Chhanda Charan Danta, Klaus Pors, Amalia Ruiz

    Mitonafide-loaded liposomes are a promising strategy to overcome the neurotoxicity observed in clinical trials for this drug. This study investigates the influence of loaded mitonafide or a dimer analogue on different liposomal formulations and their therapeutic efficacy in vitro. Physicochemical properties of the liposomes were manipulated using different loading methods (namely bilayer or core loading) and varying the rigidity of the bilayer using distinct phospholipid compositions. Our results demonstrated that the mitonafide dimer analogue had a comparable encapsulation efficiency (EE%) into the liposomes when loaded into rigid or flexible bilayers in contrast to the low mitonafide monomer EE%. A pH gradient core loading method resulted in a more efficient mechanism to load the monomer into the liposomes. DOSY NMR and spectrofluorometric studies revealed key differences in the structure of the vesicles and the arrangement of the monomer or the dimer in the bilayer or the core of the liposomes. The in vitro assessment of the formulations using MDA-MB-231 and RT-112 cells revealed that a flexible lipid bilayer allows a faster drug release, which correlated well with the spectroscopy studies. This study investigated for the first time that the characteristics of the lipid bilayer and the loading method influence the encapsulation efficacy, colloidal properties, photoactivity and stability of mono and bis-naphthalimides loaded in a liposomal carrier, essential factors that will impact the performance of the formulation in a biological scenario.